Clinical Investigations
|
|
- Cassandra Evans
- 5 years ago
- Views:
Transcription
1 Clinical Investigations Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation Address for correspondence: Laura Immordino, MD 100 E. Lancaster Avenue Wynnewood, PA Laura Immordino, MD; Stuart Connolly, MD; Harry Crijns, MD; Denis Roy, MD; Alessandro Capucci, MD; David Radzik, MD; Etienne Aliot, MD; Stefan Hohnloser, MD; Peter Kowey, MD Department of Cardiology (Immordino, Kowey), Lankenau Medical Center, Wynnewood, Pennsylvania; Department of Cardiology (Connolly), McMaster University, Hamilton, Ontario, Canada; Department of Cardiology (Crijns), Academic Hospital Maastricht, Maastricht, The Netherlands; Department of Cardiology (Roy), Montréal Heart Institute, Montréal, Québec, Canada; Department of Cardiology (Capucci), University of Ancona, Ancona, Italy; Research & Development, Cardiology, sanofi-aventis (Radzik), Bridgewater, New Jersey; Department of Cardiology (Aliot), Central Hospital, University of Nancy, Nancy, France; Department of Cardiology (Hohnloser), J.W. Goethe University, Frankfurt, Germany Background: Multiple studies have shown that amiodarone is effective in treating atrial fibrillation (AF), but is associated with a relatively high incidence of side effects; however, due to amiodarone s long elimination half-life ( days), physicians may hesitate to start other drugs until it has fully cleared. Hypothesis: A rapid switch from amiodarone to dronedarone is feasible. Methods: EURIDIS and ADONIS were double-blind, multinational, parallel-group trials comparing the efficacy and safety of dronedarone with placebo over 12 months. This retrospective subanalysis of EURIDIS/ADONIS compared the effects of dronedarone in patients discontinuing amiodarone within 2 days before randomization ( rapid switch ) with results in patients who had received no amiodarone during the 2 months preceding randomization. Results: In total, 1237 patients were enrolled ( rapid switch, n = 154; no amiodarone, n = 1014). In both the rapid switch and the no amiodarone groups, dronedarone users had significantly lower AF recurrence than patients receiving placebo (HR = 0.64, 95% CI, ; P = and HR = 0.79, 95% CI, ; P = , respectively). Dronedarone users had a higher incidence of bradyarrhythmic events than placebo-treated patients. A rapid switch from amiodarone to dronedarone was associated with a higher incidence of serious heart failure events and heart failure hospitalizations versus all other groups. Overall event rates were low and there was no significant difference in total adverse event rates or deaths between groups. Conclusion: In this patient population, a switch from amiodarone to dronedarone within a 2-day time frame might be feasible in certain patient categories, but further investigation is warranted. Introduction Multiple studies have shown that amiodarone is more effective than other antiarrhythmic drugs in maintaining sinus rhythm in patients with persistent or paroxysmal atrial fibrillation (AF). 1,2 However, due to the relatively high incidence of side effects, amiodarone has been recommended as second-line therapy, except in patients with significant left ventricular hypertrophy or heart failure Additional Supporting Information may be found in the online version of this article. The ADONIS/EURIDIS studies and this post hoc analysis were funded by sanofi-aventis. The authors have no other funding, financial relationships, or conflicts of interest to disclose. 88 (HF). 3,4 Additionally, amiodarone s large volume of distribution (often requiring weeks to reach maximal effectiveness) and its long elimination half-life ( days) 5 may cause physicians to hesitate starting other antiarrhythmics until amiodarone has fully cleared. There is a paucity of information about switching from amiodarone to other agents. Dronedarone is a noniodinated benzofuran derivative, with a pharmacologic profile similar to amiodarone s but with different relative effects on individual ion channels. 6 Compared with amiodarone, dronedarone is less lipophilic, resulting in a smaller volume of distribution and a significantly attenuated elimination half-life. Dronedarone has been shown to prolong time to first AF recurrence vs placebo 7 9 and to reduce cardiovascular hospitalizations in patients with nonpermanent AF. 10 An increased risk of fatal cardiovascular events has been Received: June 28, 2012 Accepted with revision: November 21, 2012
2 documented in patients with severe congestive HF and in patients with permanent AF taking dronedarone. 11 In addition, a few cases of liver toxicity have been reported in postmarketing surveillance; however, no organ toxicity was observed during clinical development, and dronedarone had a low proarrhythmic potential. The large clinical program conducted for dronedarone in disparate populations has helped define the indications and contraindications of this agent. Dronedarone is approved in the United States for patients with a history of paroxysmal or persistent AF to reduce the risk of hospitalization for AF in patients in sinus rhythm. 12 In Europe, it is approved for the maintenance of sinus rhythm after successful cardioversion in patients with a history of paroxysmal or persistent AF or atrial flutter (AFL). 13 Dronedarone contraindications in the United States include permanent AF, symptomatic HF with recent decompensation requiring hospitalization, or New York Heart Association class IV symptoms. 12 In Europe, contraindications include any history of or current HF or left ventricular systolic dysfunction. 13 Dronedarone has a class 1, level A recommendation in the updated 2012 European Society of Cardiology guidelines for patients with recurrent AF as a moderately effective antiarrhythmic agent for the maintenance of sinus rhythm. 14 Because dronedarone has a better long-term safety profile than amiodarone, 15 many physicians have been interested in switching patients from long-term amiodarone to dronedarone. However, there has been concern over potential additive effects of dronedarone, such as QT prolongation and bradycardia, if initiated amiodarone has cleared. Trials investigating the optimal timing of therapy switch Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation (ARTEMIS Load) and Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation (ARTEMIS AF LT) have recently completed and results are awaited. Currently, no published data are available to help physicians manage switching from amiodarone to dronedarone. Here we report a retrospective, post hoc, exploratory subanalysis of the European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm (EURIDIS) and American-Australian-African Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADO- NIS) studies. 8 We aimed to document the effects of rapid switching from amiodarone to dronedarone (amiodarone discontinuation 2 days before randomization) in patients with AF to determine the safety of early dronedarone initiation after amiodarone discontinuation. Methods Study Design Both EURIDIS and ADONIS were multinational, placebocontrolled, double-blind, parallel-group trials. 8 The efficacy and safety of dronedarone 400 mg twice daily (bid) were compared with placebo in 828 and 409 patients with AF, respectively, with a 12-month follow-up. Inclusion and exclusion criteria for these studies have been published. 8 Prior treatment with amiodarone was permitted, and patients could be enrolled immediately after amiodarone discontinuation, with no protocol restrictions for amiodarone washout; with other antiarrhythmics (Vaughan-Williams class I and III), withdrawal had to be 5 plasma half-lives prior to first study-drug administration. Eligible patients were randomized 2:1 to dronedarone 400 mg bid or placebo. Vital signs, symptoms, and electrocardiograms (ECG) were assessed/performed on days 7, 14, and 21, and at 2, 4, 6, 9, and 12 months. All patients were given transtelephonic ECG monitors; ECGs were transmitted on days 2, 3, and 5, at months 3, 5, 7, and 10, and whenever symptoms occurred. All ECGs (including transtelephonic) were centrally adjudicated. Subanalysis This retrospective, post hoc, exploratory subanalysis of the EURIDIS and ADONIS databases focused on 2 main groups: patients who discontinued amiodarone within 2 days before randomization to dronedarone 400 mg/placebo bid ( rapid switch ) and patients who had received no prior amiodarone during the 2 months preceding randomization ( no amiodarone ). Any potential amiodarone use occurring >2 months before randomization was considered as no amiodarone, as the remnant effect is likely minimal after 2 months of washout. The strongest contrast in terms of efficacy and safety parameters was expected between these 2 groups. Parameters compared were time to first recurrence of AF/AFL within 12 months from randomization, defined as an episode lasting 10 minutes as indicated by 2 consecutive 12-lead ECGs or transtelephonic ECG monitor tracings reviewed by a core laboratory, heart rate (HR) during the first recurrence of AF/AFL, and incidence and type of adverse events (AEs), which included bradycardia, QT prolongation, HF, overall cardiac events, gastrointestinal events, and changes in thyroid and creatinine levels. A small number of patients discontinued amiodarone >2 days but <2 months before randomization ( intermediate switch ). The small size of this group resulted in wide confidence intervals (CI) for the parameters analyzed. No meaningful comparisons with the other groups were therefore possible; thus, only descriptive analysis of the demographic characteristics is presented. Statistical Analysis Analyses were performed according to a modified intentionto-treat principle, with all randomized patients who received 11 doses of study drug included. As amiodarone treatment during the 2 months preceding randomization was a stratification variable, patients were classified as having received amiodarone or not before randomization according to their stratification factor. Time to first AF/AFL was estimated using the Kaplan-Meier method and compared via the log-rank test. Hazard ratios with 95% CIs were estimated using the Cox proportional hazard model. Relative risks (RR) and 95% CIs of AEs were calculated in the rapid-switch and no-amiodarone groups, and P values of interaction between amiodarone intake and treatment are based on logistic regression. All reported P values are 2-tailed, and statistical significance was assumed at P <
3 Figure1. Schematic representation showing disposition of patients enrolled in the EURIDIS and ADONIS trials. Results Of the 1237 patients enrolled in the EURIDIS and ADONIS studies, 223 had previously received amiodarone and 1014 had not received amiodarone for 2 months preceding randomization (Figure 1). Patient demographics and baseline characteristics are summarized in Table 1. Slight differences between groups in hypertension, structural heart disease, coronary artery disease, valvular heart disease, or cardiovascular-medication use did not appear to be clinically meaningful. A higher percentage of patients in the no-amiodarone group had lone AF vs those in the rapid-switch group. Any differences are not unexpected in a retrospective analysis. Efficacy: Time to First Atrial Fibrillation/Atrial Flutter Recurrence Dronedarone users in both groups had a significantly lower incidence of AF/AFL recurrence at 12 months vs patients randomized to placebo (64.3% vs 80.4% in the rapid-switch group and 63.1% vs 72.2% in the no-amiodarone group (online Figures 1A and 1B). Heart Rate During First Recurrence of Atrial Fibrillation/Atrial Flutter Of patients receiving placebo, those with prior amiodarone use had a mean HR of 109 bpm vs 119 bpm in those without prior amiodarone use. In patients taking dronedarone, those with prior amiodarone use had a mean HR of 102 bpm vs 104 bpm in those without prior amiodarone use. Safety and Tolerability: Overall Adverse Events In the rapid-switch group, switching from amiodarone to dronedarone within 48 hours was not associated with a higher incidence of treatment-emergent AEs vs switching to placebo (Table 2). Incidence rates of serious AEs and events leading to hospitalization or death were similar across all groups. There was a higher incidence of AEs leading to drug discontinuation in dronedarone vs placebo users in both groups; however, this was not statistically significant (9.1% vs 6.3% in the no-amiodarone group and 8.2% vs 3.6% in the rapid-switch group). Bradyarrhythmic Events: There was a higher incidence of bradyarrhythmic events in dronedarone-treated patients vs placebo-treated patients, regardless of prior amiodarone use (Table 2). Overall bradyarrhythmic-event rates were similar among all dronedarone users; however, the rate of these events leading to drug discontinuation was significantly higher in the rapid-switch group than in the noamiodarone group (3.1% vs 0.7%; RR: 4.16, 95% CI: ) (Table 3). Overall, the proportion of patients with serious bradyarrhythmic events and those leading to hospitalization was low. Overall Cardiac Events: Overall cardiac event rates were similar among the rapid-switch and no-amiodarone groups. Patients in the rapid-switch/dronedarone group tended to have more serious cardiac events and cardiac events leading to drug discontinuation and hospitalization than all other groups; however, these were not statistically significant (Tables 2 and 3). Heart Failure Events: Overall HF-event rates did not significantly differ among patients in the rapid-switch and no-amiodarone groups (Table 2). There were more serious HF events and HF hospitalizations in the rapidswitch/dronedarone group compared with other groups (Tables 2 and 3; RR: 5.95, 95% CI: ). However, no HF cases led to death or drug discontinuation in dronedarone-treated patients, and 1 fatal case of HF was reported in the no-amiodarone/placebo group (Table 2). Electrocardiographic Abnormalities: Overall, dronedarone users had a higher incidence of bradycardia documented on ECG, defined by a HR 50 bpm and a drop of 15 bpm from baseline (10.5% vs 5.7% with placebo). However, 90
4 Table 1. Demographics and Baseline Characteristics According to Previous Intake of Amiodarone Per Stratification Factor (All Randomized and Treated Patients) Rapid Switch Intermediate Switch No Amiodarone N = 56 N = 98 N = 17 N = 35 N = 334 N = 680 Demographics Mean age, y (SD) 61.8(9.8) 64.4(8.7) 64.8(9.3) 65.9(12.6) 62.1(11.4) 63.2(10.9) <65, % , % Women, % Cardiovascular history, % Hypertension Structural heart disease Lone AF CAD Valvular heart disease Pacemaker Dilated cardiomyopathy Baseline medication, % Oral anticoagulant β-blocker ACEI or ARB Chronic antiplatelet therapy Diuretic Statin Digitalis Moderate inhibitor of CYP3A NSAID Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; CYP3A4, cytochrome P450 3A4; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation. the incidence of bradycardia in all dronedarone users was similar, regardless of prior amiodarone use (10.5% in rapidswitch group vs 10.9% in the no-amiodarone group). Amiodarone users had a higher mean corrected QT interval (QTc) at baseline than nonusers (435 ms vs 400 ms). Those who switched to dronedarone had a relatively stable QTc interval over the first month, with modest decreases at the 4-, 9-, and 12-month follow-ups (Figure 2A). Those who switched to placebo had a relatively stable QTc interval over the first month, followed by a more profound decrease in QTc interval at the 4-month follow-up and subsequent stability in the QTc interval over the remainder of follow-up. Patients in the no-amiodarone/dronedarone group had an increased QTc interval at the 7-day follow-up, then relative stability of the QTc interval over the next 12 months (Figure 2A). Overall, dronedarone users had similar QTc intervals at 12 months, regardless of prior amiodarone use. The incidence of prolonged QTc (ie, QTc 500 ms) was higher in dronedarone users with recent amiodarone use vs those without (7.9% vs 4.4%). There were no episodes of torsades de pointes. Creatinine Levels: The rapid-switch/placebo patients had decreases in serum creatinine over the 12 months following randomization. rapid-switch/dronedarone patients had slight increases in serum creatinine, but to a lesser extent than no-amiodarone/dronedarone patients (Figure 2B). Thyroid Profile: Placebo-treated patients in the rapidswitch group had the highest rate of abnormal thyroidfunction tests, with 24.1% experiencing a change in thyroid-stimulating hormone levels outside normal range and 14.8% with a change in free-t3 levels (online 91
5 Table 2. AEs According to Amiodarone Intake Per Stratification Factor (All Randomized and Treated Patients From Rapid-Switch and No-Amiodarone Groups) Rapid Switch No Amiodarone n = 56 n = 98 RR (95% CI) n = 334 n = 680 RR (95% CI) TEAE, n (%) a 42 (75.0) 63 (64.3) 0.86 ( ) 201 (60.2) 459 (67.5) 1.12 ( ) Serious TEAE 8 (14.3) 15 (15.3) 1.07 ( ) 54 (16.2) 93 (13.7) 0.85 ( ) TEAE leading to hospitalization 8 (14.3) 15 (15.3) 1.07 ( ) 51 (15.3) 85 (12.5) 0.82 ( ) TEAE leading to death 1 (1.8) 1 (1.0) 0.57 ( ) 2 (0.6) 5 (0.7) 1.23 ( ) AE leading to premature study drug 2(3.6) 8 (8.2) 2.29 ( ) 21 (6.3) 62 (9.1) 1.45 ( ) discontinuation a,b,c Incidence of bradyarrhythmic events, n (%) d All events 0 4 (4.1) NC 9 (2.7) 35 (5.1) 1.91 ( ) Serious events 0 1 (1.0) NC 3 (0.9) 9 (1.3) 1.47 ( ) Events leading to drug discontinuation 0 3 (3.1) NC 0 5 (0.7) NC Events leading to hospitalization 0 1 (1.0) NC 3 (0.9) 9 (1.3) 1.47 ( ) Events leading to death 0 1 (1.0) NC 0 0 NC Incidence of cardiac events, n (%) e All events 10 (17.9) 18 (18.4) 1.03 ( ) 52 (15.6) 122 (17.9) 1.15 ( ) Serious events 3 (5.4) 9 (9.2) 1.71 ( ) 19 (5.7) 39 (5.7) 1.01 ( ) Events leading to drug discontinuation 1 (1.8) 3 (3.1) 1.71 ( ) 6 (1.8) 10 (1.5) 0.82 ( ) Events leading to hospitalization 2 (3.6) 9 (9.2) 2.57 ( ) 19 (5.7) 39 (5.7) 1.01 ( ) Events leading to death 1 (1.8) 1 (1.0) 0.57 ( ) 1 (0.3) 1 (0.1) 0.49 ( ) Incidence of HF events, n (%) f All events 7 (12.5) 11 (11.2) 0.90 ( ) 28 (8.4) 54 (7.9) 0.95 ( ) Serious events 1 (1.8) 6 (6.1) 3.43 ( ) 5 (1.5) 7 (1.0) 0.69 ( ) Events leading to drug discontinuation 0 0 NC 3 (0.9) 0 NC Events leading to hospitalization 1 (1.8) 6 (6.1) 3.43 ( ) 5 (1.5) 7 (1.0) 0.69 ( ) Events leading to death 0 0 NC 1 (0.3) 0 NC Incidence of GI events, n (%) g All events 8 (14.3) 15 (15.3) 1.07 ( ) 63 (18.9) 144 (21.2) 1.12 ( ) Serious events 1 (1.8) 2 (2.0) 1.14 ( ) 1 (0.3) 11 (1.6) 5.40 ( ) Events leading to drug discontinuation 0 1 (1.0) NC 7 (2.1) 9 (1.3) 0.63 ( ) Events leading to hospitalization 1 (1.8) 2 (2.0) 1.14 ( ) 1 (0.3) 11 (1.6) 5.40 ( ) Events leading to death 0 0 NC 0 0 NC Abbreviations: AE, adverse events; AF, atrial fibrillation; AFL, atrial flutter; CI, confidence interval; GI, gastrointestinal; HF, heart failure; MedDRA, Medical Dictionary for Regulatory Activities; NC, not calculated; RR, relative risk; SOC, system organ class; TEAE, treatment-emergent adverse event. AEs classified based on MedDRA selections. a Including serious AEs. b AEs leading to premature study drug discontinuation are all AEs (excluding AF/AFL) described on the End of Study form (onset date 10 d after final study drug administration). c Events beginning before first study drug intake were accounted for. d Bradyarrhythmic events selected using standardized MedDRA query bradyarrhythmia including conduct deficiencies sinus node disorders with broad selection, or preferred term, bradycardia. e Cardiac events selected using SOC cardiac disorders or vascular disorders. f HF events (narrow selection) selected using standardized MedDRA query cardiac failure. g GI events (narrow selection) selected using SOC gastrointestinal disorders. Table 1). Patients in the rapid-switch/dronedarone group had rates of abnormal thyroid function tests similar to the no-amiodarone/dronedarone and no-amiodarone/placebo groups (6% 10% had changes in thyroid-stimulating hormone levels, and 6% 9% had changes in free-t3 levels). 92
6 Table 3. AEs Among Patients Taking Dronedarone According to Prior Amiodarone Use (All Dronedarone-Treated Patients From Rapid Switch and No Amiodarone Groups) Incidence of bradyarrhythmic events, n (%) a Dronedarone-Treated Patients Rapid Switch, N = 98 No Amiodarone, N = 680 Relative Risk (95% CI) All events 4 (4.1) 35 (5.1) 0.79 ( ) Serious events 1 (1.0) 9 (1.3) 0.77 ( ) Events leading to drug discontinuation 3 (3.1) 5 (0.7) 4.16 ( ) Events leading to hospitalization 1 (1.0) 9 (1.3) 0.77 ( ) Events leading to death 1 (1.0) 0 NC Incidence of cardiac events, n (%) b All events 18 (18.4) 122 (17.9) 1.02 ( ) Serious events 9 (9.2) 39 (5.7) 1.60 ( ) Events leading to drug discontinuation 3 (3.1) 10 (1.5) 2.08 ( ) Events leading to hospitalization 9 (9.2) 39 (5.7) 1.60 ( ) Events leading to death 1 (1.0) 1 (0.1) 6.94 ( ) Incidence of HF events, n (%) c All events 11 (11.2) 54 (7.9) 1.41 ( ) Serious events 6 (6.1) 7 (1.0) 5.95 ( ) Events leading to drug discontinuation 0 0 NC Events leading to hospitalization 6 (6.1) 7 (1.0) 5.95 ( ) Events leading to death 0 0 NC Incidence of GI events, n (%) d All events 15 (15.3) 144 (21.2) 0.72 ( ) Serious events 2 (2.0) 11 (1.6) 1.26 ( ) Events leading to drug discontinuation 1 (1.0) 9 (1.3) 0.77 ( ) Events leading to hospitalization 2 (2.0) 11 (1.6) 1.26 ( ) Events leading to death 0 0 NC Abbreviations: AE, adverse event; CI, confidence interval; GI, gastrointestinal; HF, heart failure; MedDRA, Medical Dictionary for Regulatory Activities; NC, not calculated; SOC, system organ class. AEs classified based on MedDRA selections. a Bradyarrhythmic events selected using standardized MedDRA queries Bradyarrhythmia including conduct deficiencies sinus node disorders with broad selection, or preferred term, bradycardia. b Cardiac events selected using SOC cardiac disorders or vascular disorders. c HF events (narrow selection) selected using standardized MedDRA query cardiac failure. d GI events (narrow selection) selected using SOC gastrointestinal disorders. Discussion The EURIDIS and ADONIS studies demonstrated the efficacy of dronedarone in prolonging time to first AF recurrence vs placebo. 8 Retrospective analysis of these data confirms the effectiveness of dronedarone in a subset of patients who had discontinued amiodarone <2 days prior to starting dronedarone. Compared with the overall population, similar rates of AF recurrence were observed in patients in the rapid-switch group. Heart rate was slightly lower during the first recurrence of AF/AFL in the rapid-switch group vs the no-amiodarone group. Of those randomized to placebo, patients in the rapid-switch group had a lower mean HR than those in the no-amiodarone group, probably because these patients were still affected by the HR-lowering properties of amiodarone, due to its long elimination half-life. Interestingly, the rapidswitch/dronedarone patients had a mean HR only slightly lower than the rapid-switch/placebo patients, indicating a limited additive effect of dronedarone on HR in patients already treated with amiodarone. Dronedarone-treated patients had a higher incidence of bradyarrhythmic events than did placebo-treated patients. More bradyarrhythmic events causing drug discontinuation were seen in dronedarone users who had recently received 93
7 Figure2. Mean (standarddeviation)value over time for (a)qtc Fridericia (ms),and (b)creatinine levels (μmol/l) during on-treatment period (all randomized and treated patients in the rapid switch and no amiodarone groups). B, baseline; D, day; EOT, last value under treatment; M, month. amiodarone vs those with no prior amiodarone. Although the overall number of bradyarrhythmic events was low, this may be one potential drawback to a rapid switch and may indicate a subset of patients (those with borderline-low HR on amiodarone) that would benefit from a more gradual switch to dronedarone. Patients in the rapid-switch/dronedarone group also had more serious HF events and HF hospitalizations vs all other groups. Patients in the no-amiodarone/dronedarone group had HF-event rates similar to the no-amiodarone/placebo group, indicating a potential additive effect or interaction between recent amiodarone use and dronedarone. In dronedarone-treated patients, serum creatinine levels increased. A smaller increase was seen in the rapid-switch group vs the no-amiodarone group. A small rise in creatinine levels upon initiation is anticipated, as dronedarone reduces renal creatinine clearance, although without affecting the glomerular filtration rate. 15 Amiodarone produces similar changes, possibly via a similar mechanism, 16 explaining why serum creatinine decreased slightly in patients stopping amiodarone and receiving placebo but increased slightly in those receiving dronedarone. Changes in thyroid hormones in the rapid-switch group are related to the residual effects of amiodarone on 94
8 thyroid function. 17,18 The abnormalities were corrected after amiodarone discontinuation. Importantly, no changes in thyroid hormone levels were observed in patients randomized to dronedarone vs those receiving placebo. Limitations of this study include its retrospective, exploratory nature, and the small number of patients involved, limiting the statistical power. In addition, recent treatment with amiodarone prior to inclusion was not a randomized variable; it was present by definition in all rapidswitch patients and in no patients in the no-amiodarone group. Therefore, one cannot exclude the possibility that patients in the rapid-switch group had more severe heart disease to start with, as amiodarone is often prescribed in this setting. This hypothesis is supported by a slightly lower incidence of lone AF in rapid-switch patients compared with no prior amiodarone patients for both the placebo and the dronedarone subgroups. Similarly, the timing of amiodarone discontinuation prior to dronedarone initiation was at the discretion of the study physician, and a subset of patients had a delayed switch from amiodarone to dronedarone for reasons that cannot be ascertained. For these reasons, some degree of self-selection bias cannot be excluded in the rapid-switch group. Conclusion This retrospective analysis of a small subset of patients from the EURIDIS and ADONIS studies suggests that rapid switching (<48 hours) from amiodarone to dronedarone might be feasible in certain patients. Further clinical investigation will be required to determine the optimal time frame for switching drugs, and this decision will likely be on a case-by-case basis, taking individual patient characteristics into account. Acknowledgments Editorial assistance was provided by Sally Mitchell, PhD, and Sola Neunie of PPSI, and was funded by sanofi-aventis. References 1. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. JAm Coll Cardiol. 2004;43: Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. NEnglJMed. 2005;352: Wann LS, Curtis AB, January CT, et al ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31: Rätz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med. 2005;33: ; discussion Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100: Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24: Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. NEnglJMed. 2007;357: Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation [published corrections appear in NEnglJMed. 2009;360:2487 and 2011;364:1481]. N Engl J Med. 2009;360: Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. NEnglJMed. 2008;358: Connolly SJ, Crijns HJ, Torp-Pedersen C, et al; ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120: Multaq [prescribing information]. Bridgewater, NJ: sanofiaventis; Multaq [summary of product characteristics]. Paris, France: Sanofi; AJ Camm, GY Lip, De Caterina R, et al focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;14: Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010:21: Pollak PT, Sharma AD, Carruthers SG. Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol. 1993;36: Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007;120: Cohen-Lehman J, Dahl P, Danzi S, et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6: Clin.Cardiol.36,2,88 95(2013) 95
Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?
Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward? James A. Reiffel, M.D. Introduction In July 2009, the federal Food and Drug Administration (FDA) approved the
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationDronedarone: Need to Perform a CV Outcome Safety Study
Dronedarone: Need to Perform a CV Outcome Safety Study Gerald V. Naccarelli M.D. Consultant: Glaxo-Smith-Kline, Pfizer, Sanofi, Boehringer-Ingelheim, Daiichi-Sankyo, Bristol Myers Squibb, Otsuka, Janssen
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationUpdate on Dronedarone and Cardiovascular Outcomes
Update on and Cardiovascular Outcomes Dr. Stuart Connolly MD McMaster University Hamilton Ontario Disclosure: Research grants, speaker fees and consulting honoraria from sanofi aventis has key structural
More informationReviews. Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation
Reviews Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation Address for correspondence: Stefan H. Hohnloser, MD Department of Cardiology J.W. Goethe University Hospital
More informationATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular
1 ATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationDronedarone in patients with congestive heart failure: insights from ATHENA
European Heart Journal (2010) 31, 1717 1721 doi:10.1093/eurheartj/ehq113 CLINICAL RESEARCH Heart failure/cardiomyopathy Dronedarone in patients with congestive heart failure: insights from ATHENA Stefan
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationDronedarone in the Post-Pallas Era. Jorge E. Schliamser, MD Carmel Medical Center Haifa
Dronedarone in the Post-Pallas Era Jorge E. Schliamser, MD Carmel Medical Center Haifa Disclosures None Dronedarone is a multichannel blocker Dronedarone possesses electrophysiologic characteristics of
More informationDronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?
Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium? Abstract James A. Reiffel, M.D. Department of Medicine, Division of Cardiology, Columbia University Medical Center Dronedarone is a derivative
More informationPRESCRIBING ALERT
www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring
More informationDronedarone for the management of atrial fibrillation
Published 2 March 2011, doi:10.4414/smw.2011.13158 Cite this as: Dronedarone for the management of atrial fibrillation Roman Brenner, Etienne Delacrétaz Department of Cardiovascular Medicine, University
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationRole of Dronedarone in Atrial Fibrillation: More Questions Than Answers
Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers Daniel E. Hilleman, Pharm.D., FCCP, and Aryan N. Mooss, M.D. Key Words: dronedarone, atrial fibrillation, sinus rhythm, hypertension,
More informationDronedarone and Atrial Fibrillation: A Critical Review
Clinical Medicine Reviews in Vascular Health Review Dronedarone and Atrial Fibrillation: A Critical Review David Singh 1, Eugenio Cingolani 2, Sanjay Kaul 2 and Steven Singh 3 1 University of California
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Effect of on Cardiovascular Events in Atrial Fibrillation Stefan H. Hohnloser, M.D., Harry J.G.M. Crijns, M.D., Martin van Eickels,
More informationDronedarone( What%is%the%future?!
Dronedarone( What%is%the%future?! DRUG(PROPHYLAXIS(OF(AF:( FOCUS(ON(DRONEDARONE( Friday(16>10>2015( Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research grants, consulting
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationArrhythmia/Electrophysiology
Arrhythmia/Electrophysiology Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationSafety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
Clinical Medicine Insights: Cardiology Expert Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Safety and Efficacy of Dronedarone in the Treatment of
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationAntiarrhythmic agents in 2014
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Antiarrhythmic agents in 2014 Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice, Italy
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationComparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 54, No. 12, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.04.085
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationPALLAS. Dronedarone on Top of Standard Therapy. Stuart J. Connolly MD. on behalf of the PALLAS investigators
PALLAS Permanent Atrial FibriLLAtion Outcome Study using on Top of Standard Therapy Stuart J. Connolly MD on behalf of the PALLAS investigators http://clinicaltrials.gov Number: NCT01151137 1 Disclosure
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationArrhythmia: Open Access
Arrhythmia: Open Access Arrhythmia: Open Access Sawh and Rashid, 2016, 1:2 Research Article Open Access The Safety and Efficacy of Sotalol in the Management of Acute Atrial Fibrillation : A Retrospective
More informationAmiodarone Prescribing and Monitoring: Back to the Future
Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran
More informationBenjamin/Circ May 2008/p948/Fig A
1 2 Benjamin/Circ May 2008/p948/Fig A As shown here, data from the Framingham Heart Study have helped to establish an association between atrial fibrillation and excess mortality that is independent of
More informationSUPPLEMENTARY INFORMATION
Table S1 Sex- specific differences in rate- control and rhythm- control strategies in observational studies Study region Study period Total sample size Sex- specific results Ozcan (2001) 1 Mayo Clinic,
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationMaintenance of sinus rhythm is a necessary goal in many
A Randomized, Placebo-Controlled Study of Vernakalant (Oral) for the Prevention of Atrial Fibrillation Recurrence After Cardioversion Christian Torp-Pedersen, MD; Dimitar H. Raev, MD, PhD; Garth Dickinson,
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationSafety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter
Journal of the American College of Cardiology Vol. 44, No. 1, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.03.047
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 02/15/2010
ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 02/15/2010 Grantor: CDER IND/IDE Number: 49,484 Serial Number: 0278 Efficacy & Safety of Dronedarone Versus Amiodarone
More informationDECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical
DECLARATION OF CONFLICT OF INTEREST Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical ESC Congress Paris, France August 27-31, 2011 Risk & Complications of AADs for Rhythm
More informationMehta Hiren R et al. IRJP 2 (3) DRONEDARONE: A NEW MOLECULE FOR ATRIAL FIBRILLATION Patel Paresh B 1, Patel Kamlesh C 1, Mehta Hiren R 2 *
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 8407 Available online http://www.irjponline.com Review Article DRONEDARONE: A NEW MOLECULE FOR ATRIAL FIBRILLATION Patel Paresh B 1, Patel Kamlesh C
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationThere are future perspectives in the pharmacological treatment of arrhythmias
There are future perspectives in the pharmacological treatment of arrhythmias George Andrikopoulos, MD, PhD, FESC, Cardiologist, Director, 1st Department of Cardiology/ Department of Electrophysiology
More informationAntiarrhythmics for Atrial Fibrillation: Practical Implications of Latest Clinical Developments CME
Antiarrhythmics for Atrial Fibrillation: Practical Implications of Latest Clinical Developments CME A. John Camm, MD; Stuart J. Connolly, MD; Jean-Yves F. Le Heuzey, MD CME Released: 12/08/2011; Valid
More informationPrimary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation
Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation Anne B. Curtis, MD, FACC, FHRS, FACP, FAHA Charles and Mary Bauer Professor, Chair,
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationT. Barry Levine & Thomas Giles & David Radzik & Jalal K. Ghali
Cardiovasc Drugs Ther (2010) 24:449 458 DOI 10.1007/s10557-010-6251-y Effect of Dronedarone on Exercise Capacity and Cardiac Function in Patients With Severe Left Ventricular Dysfunction and Compensated
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAtrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen
Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder The Netherlands Madrid Europace June 2011 Conflict of interests Research grants from Medtronic, SJM, Biotronik, Boston,
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationManagement of atrial fibrillation in heart failure
Nationale hartfalendag 2017 Zeist Management of atrial fibrillation in heart failure Isabelle C Van Gelder University of Groningen University Medical Center Groningen The Netherlands Disclosures Grant
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationThe objective of this study was to determine the longterm
The Natural History of Lone Atrial Flutter Brief Communication Sean C. Halligan, MD; Bernard J. Gersh, MBChB, DPhil; Robert D. Brown Jr., MD; A. Gabriela Rosales, MS; Thomas M. Munger, MD; Win-Kuang Shen,
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationEtienne Aliot. University of Nancy - France
Etienne Aliot University of Nancy - France Disclosures Consulting fees : - Bayer, Boehringer Ingelheim,GSK, MedaPharma, Pfizer/BMS,Sanofi Aventis. - Biotronik,Medtronic,St Jude Medical. Electrical vs Pharmacological
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationDronedarone for the treatment of atrial fibrillation and atrial flutter
National Institute for Health and Clinical Excellence Dronedarone for the treatment of atrial fibrillation and atrial flutter Comment 1: the draft remit Appropriateness Sanofi-aventis Sanofi-aventis believe
More informationL. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL.
Prognosis in patients with atrial fibrillation and CHA 2 DS 2 VASc score=0 in a real world community based cohort study: Loire Valley Atrial Fibrillation project L. Fauchier (1), S. Taillandier (1), I.
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationRandomized, double blind, placebo-controlled, for the maintenance of normal sinus rhythm in. FORωARD
Randomized, double blind, placebo-controlled, independent study to test the efficacy of n-3 3PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. FORωARD (Fish
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationAsymptomatic or Silent Atrial Fibrillation. Frequency in Untreated Patients and Patients Receiving Azimilide
Asymptomatic or Silent Atrial Fibrillation Frequency in Untreated Patients and Patients Receiving Azimilide Richard L. Page, MD; Thomas W. Tilsch, BS; Stuart J. Connolly, MD; Daniel J. Schnell, PhD; Stephen
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More information